S-1 is administered orally at 80mg/m2/day for 14 consecuitive days followed by a 7 day rest. L-OHP is given intravenously on days 1, at a dose of 130mg/m2/day.Bevacizumab is given intravenously on day

3 trials

Sponsors

Morohashi Hajime, Aomori Colorectal Cancer Study (ACCS) group

Conditions

Colorectal cancer with synchronous liver metastasisUnresectable rectal cancer by organ-preserved TMEcolorecal cancer

Phase 2

Study of resection of primary colorectal caner and synchronous liver metastasis after SOX + Bmab

Active, not recruitingJPRN-jRCTs021180034

Morohashi Hajimecolorecal cancer

Start: 2018-04-04Target: 28Updated: 2026-06-29

Unknown Phase

Phase II study of surgery after S-1 + oxaliplatin + bevacizumab therapy for unresectable rectal cancer by organ-preserved TME

Active, not recruitingJPRN-UMIN000031626

Aomori Colorectal Cancer Study (ACCS) groupUnresectable rectal cancer by organ-preserved TME

Start: 2018-03-05Target: 32Updated: 2026-06-29

Phase II study of resection of primary colorectal caner and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy

RecruitingJPRN-UMIN000032102

Aomori Colorectal Cancer Study (ACCS) groupColorectal cancer with synchronous liver metastasis

Start: 2018-04-01Target: 28Updated: 2026-06-29

Related Papers

Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + bevacizumab (Bmab) therapy and adjuvant S-1 chemotherapy

Annals of Oncology2018-10-01

Phase II study of surgery after S-1 + oxaliplatin +bevacizumab therapy for unresectable rectal cancer by organ-preserved TME

Annals of Oncology2018-10-01